Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Ann Thorac Surg. 2010 Mar;89(3):864-9. doi: 10.1016/j.athoracsur.2009.09.047.
The 5-year survival rate of pathologic stage IA non-small cell lung cancer (NSCLC) is excellent; however, up to 10% of patients with pathologic stage IA NSCLC still relapse postoperatively and die. This study retrospectively analyzed the clinicopathologic features of patients with pathologic stage IA NSCLC to identify the prognostic factors and investigate the effect of a combination of intratumoral vessel invasion and tumor size.
From December 1991 to December 2003, 217 consecutive patients with stage IA NSCLC were selected, and disease-free survival (DFS) was analyzed.
Intratumoral blood vessel invasion (BVI) was identified as an independent poor prognostic factor (p = 0.0006). The relative risk for patients with BVI was 4.599 times higher than that for patients without BVI (95% confidence interval, 1.913 to 11.056). According to the new T N M system, the difference in DFS between the patients with and without BVI was statistically significant, not only in tumors exceeding 2 cm (T1b with BVI vs T1b without BVI, p = 0.0020) but also in tumors smaller than 2 cm (T1a with BVI vs T1a without BVI, p < 0.0001). The survival curve of T1b patients without BVI was similar to that of T1a patients without BVI (p = 0.0892). Distant recurrence was frequently observed in both T1a and T1b patients with BVI.
BVI is an independent poor prognostic factor in patients with pathologic stage IA NSCLC. These T1a and T1b patients with BVI both might benefit from adjuvant chemotherapy.
病理分期为 IA 期的非小细胞肺癌(NSCLC)患者 5 年生存率极佳;然而,仍有 10%左右的 IA 期 NSCLC 患者术后复发并死亡。本研究回顾性分析了 IA 期 NSCLC 患者的临床病理特征,以确定预后因素,并探讨肿瘤内血管侵犯和肿瘤大小联合的影响。
从 1991 年 12 月至 2003 年 12 月,选择了 217 例连续的 IA 期 NSCLC 患者,并分析了无病生存率(DFS)。
肿瘤内血管侵犯(BVI)被确定为独立的不良预后因素(p = 0.0006)。BVI 患者的相对风险是无 BVI 患者的 4.599 倍(95%置信区间,1.913 至 11.056)。根据新的 TNM 系统,BVI 患者与无 BVI 患者之间的 DFS 差异具有统计学意义,不仅在肿瘤直径大于 2cm(T1b 有 BVI 与 T1b 无 BVI,p = 0.0020),而且在肿瘤直径小于 2cm(T1a 有 BVI 与 T1a 无 BVI,p < 0.0001)。无 BVI 的 T1b 患者的生存曲线与无 BVI 的 T1a 患者相似(p = 0.0892)。有 BVI 的 T1a 和 T1b 患者均常发生远处复发。
BVI 是 IA 期 NSCLC 患者的独立不良预后因素。这些有 BVI 的 T1a 和 T1b 患者可能都受益于辅助化疗。